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Background: The prevalence of latex allergy varies according to the population studied from 3% to 64%. No data
exist in the present literature about elderly people because they were not considered among populations at risk.
We report a retrospective observational study of 88 elderly patients of our centre of Dermatology and Allergology
at Policlinico Umberto I, University of Rome, Sapienza.
Results: First and second level diagnostic tests showed latex positivity in 11,4% of patients studied for latex allergy
in the elderly population.
Conclusions: Our study demonstrates a prevalence of elderly-latex sensitization of 11,4%, showing that allergy to
latex is a growing disease that can occur at any age. So, we propose these patients as an additional risk category
for latex allergy.
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Natural rubber latex (NRL) is a natural sap of the rubber
tree (Hevea brasiliensis), which grows in Africa and the
Malaysian peninsular [1,2]. NRL coagulates on exposure
to air, giving rise to spherical polyisoprene droplets coated
with a layer of water soluble proteins [3]. This compound
is filtered and preserved with one of the following: 1) so-
dium sulfite; 2) formaldehyde; 3) ammonia (0.05–2.0%); or
4) ammonia and 0.025% of a 1:1 mixture of zinc oxide and
tetramethylthiuram disulfide in order to alkalinize the pH,
which increases stability of NRL and slows down the
growth of microorganisms [4-7].
Latex allergy may develop through two major pathways:
a) one that is dependent on sensitization to latex protein
with a type I immunoglobulin E (IgE)-mediated hypersen-
sitivity reaction, b) one that depends on chemicals mixed
with the latex protein such as thiurams, mercapto-
benzathiazoles, that are the cause of type IV delayed hyper-
sensitivity reactions [8].
The prevalence of latex allergy varies according the
population studied from 3% to 64%, being highest in groups
such as healthcare workers, rubber industry workers, pa-
tients who have had multiple surgeries, and children with* Correspondence: teresa.grieco@uniroma1.it
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reproduction in any medium, provided the orbladder extrophy or myelodysplasia. It is estimated that
more than 15 million people suffer from latex allergy
worldwide [9-11]. Among the general population the range
of sensitization is between 5% and 10%, while in the health-
care workers it is approximately 10 to 17% [12]. Allergy risk
is increased in individuals who have cumulatively prolonged
exposure to latex for several reasons, such as exposure at
work, in the home environment and while engaging in
hobbies.
Although latex allergy is most common in adults, no
data are available in the present literature on the incidence
in elderly people, essentially because they were not consid-
ered as risk-population. However, we have clinical evidence
that after latex contact, this group of patients may develop
severe reactions. Therefore, we report a retrospective ob-
servational study of elderly population arrived at our
Centre of Dermatology and Allergology at the Policlinico
“Umberto I” Hospital of the University of Rome, Sapienza.
The present study aims to determine:
– latex allergy prevalence in elderly people
– the peak of prevalence in relation to sex and age
– class sensitization in our patients
– diseases related to latex allergy
– diseases due to latex allergy in our population of
patients.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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The study "latex sensitization in elderly: allergological
study and diagnostic protocol. Retrospective study." was
approved by the ethics committee of the University of
Rome “Sapienza” (3089/13/02/2014).
Study population
From January 2003 to May 2012, 912 patients joined the
investigation of first level (RAST) for latex sensitization.
Of these 912 patients we selected, on the basis of old
age, 88 aged 65 or over, representing our cases study. In
particular, we selected 27 males and 61 females, aged
from 65 to 86 years whose average age was 71,7 years.
The patients were subjected to the following study
protocol:
– clinical history according to American Latex Allergy
Association test [13];
– cutaneous clinical examination;
– first level blood tests, according to good practice
referred to in the literature [14,15], although there
are not any real guidelines:
 RAST test to detect latex-specific IgE;
 specific IgE recognition patterns to recombinant
Hevea brasiliensis (Hev b).– If RAST was negative, second level in vivo tests
were performed:
 latex-skin prick test;
 patch test in line with European standard series;
 rubber additional series;
 NRL additional series;
 latex specific series “TRP-LTX 960”;
 patch by patch with latex gloves.– Challenge tests are not performed for severe adverse
reactions risk referred to in the literature.
Clinical history
Patients were asked to collect the following information:
– demographic data (name, age, gender, employment
status);
– work-related data and after-work activities;
– number of surgical interventions undergone;
– previous respiratory disease;
– family and personal history of atopy;
– cutaneous, nasal, ocular or respiratory symptoms
and their association with the workplace and/or
with the use of latex gloves or with some
hobbies;
– allergic reactions after contact with latex products
or with fruits related to latex allergy (banana, kiwi,
chestnut, and avocado);– use of latex gloves or other materials;
– previous diagnosis of latex allergy.
The same data can also be collected by submitting a
questionnaire to the patient and the questionnaire from
the American Latex Allergy Association was quite help-
ful [13].
Rast and protein microarray test procedure
We used the ImmunoCAP system to determine serum
specific IgE to latex and its main allergens in recombinant
form (rHev b 1, rHev b 6.01, rHev b 6.02, rHev b 6.03,
rHev b 8 and rHev b 11). A reading of more than 0.35
kUA/L was considered positive. In particular, distinguish 7
sensitization classes: class 0 (<0.35 kUA/L), class I (0,35-
0,70 kUA/L), class II (0,71-3,50 kUA/L), class III (3,51-
17,50 kUA/L), class IV (17,51-50 kUA/L), class V (51-100
kUA/L), class VI (>100 kUA/L).
Skin prick test
The skin test procedures are performed with a lancet
pricking the skin on the forearm through a drop of latex
extracts (ALK-ABELLO’®) at sequential concentrations
of 0.001-1 mg/mL of latex protein. The results are read
after 15 minutes and are compared to a negative saline
control and histamine. The presence of a wheal with an
average diameter equal to or greater than 3 mm [16] was
interpreted as a positive reaction.
Patch test
The allergens are applied to Finn chambers. The Finn
chambers are placed on the upper back and removed after
72 hours (D3) for European and rubber series (MERK®).
While reading for latex patch test were performed after
30 minutes, 48 hours (D2) and 96 hours (D4). A com-
mercial non-ammoniated latex (ALK-ABELLO®) was used.
Positive reactions were evaluated according to International
Contact Dermatitis Research Group recommendations
[17]. Irritant reactions were considered negative. The pa-
tients were also tested with a patch by patch with a latex
glove and were also studied with a latex specific series
“TRP-LTX 960” (EUROMEDICAL®).
Statistical analysis
The cases considered was analyzed statistically with descrip-
tive statistical index (percentage, average). In particular it
was calculated the prevalence of subjects with latex-RAST
test and latex-SPT positivity. This prevalence was calculated
at 95% confidence interval with the Wilson method.
The association between latex sensitization and gender
and age, as well as with certain disorders (eg, urticaria)
was carried out using the chi square test of Pearson or
the Fish’s exact test where appropriate. The level of the
first type error (α) has been set equal to 0.05.
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From a total of 88 (27 male, 61 female) elderly patients,
aged from 65 to 86 years whose average age was 71,7, 46
of them (52,3%) displayed only cutaneous symptoms:
 irritant/allergic contact dermatitis
 generalized urticaria
 angioedema;




2 patients (2,2%) reported severe generalized reaction
 glottis oedema
 anaphylactic shock;
3 patients (3,4%) reported an adverse reaction during
surgery;
1 patient (1,2%) reported adverse drug reactions;
24 patients (27,3%) showed polisensitivity for aeroaller-
gens such as dermatophagoides, grass pollen and tree
pollen.
First level diagnostic test such as latex-RAST test, showed
latex positivity in 8 patients, 4 males and 4 females.
Four subjects had a RAST value of I class, 3 of II class
and only 1 of III class, with a mean level of 3,5 kUA/L
(0.35-100 kUA/L).
In particular, 4 of these positive patients were aged in
the range from 75 to 79 years, 2 patients were aged in
the range from 65 to 69 years and the other 2 patients
in the range from 80 to 84 years with a peak of preva-
lence from 75 to 79 years.
Microarray-based assessment of serum specific-IgE
recognition patterns detected a positive results for the
following NRL proteins: 2 patients were rHev b 8 and
only 1 patients was rHev b 11 positive.
The second level in vivo investigation tests were per-
formed on 80 serum specific-IgE negative patients. The
skin prick test revealed 2 more females with positivity,
for a total of 10 patients positive to latex, with a preva-
lence of 11.4% evaluable in population with a 95% confi-
dence interval between 6.3% and 19.7%. This prevalence
is not influenced neither by sex nor age since there is no
a significant difference between these variables. In fact,
using the chi square test of Pearson or the Fish’s exact
test, we have linked the latex sensitization with different
diagnoses and sex of patients, but because of the sample
is too small, has not revealed any significant results.
Although there are not significant differences regard to
diagnosis, we found a higher percentage of sensitizationamong patients who reported urticaria and angioedema,
followed by adverse drug reactions (ADR), contact derma-
titis and finally asthma and polisensitivity to aeroallergens.
All patients were also patch tested according to European
standard series, NRL, additional rubber series, patch by
patch with a latex gloves, and with a latex specific series
“TRP-LTX 960” (EUROMEDICAL®).
The European series showed 1 positivity for nickel sul-
phate in a woman whereas, all NRL-patch tests and patch
by patch with a latex gloves resulted negative.
Additional rubber series showed positive results to para-
phenilendiamine and thiuram mix allergens in to 2 females.
“TRP-LTX 960” showed positive results in 1 female, that
had also displayed a positivity to Thiuram.
We did not perform provocation tests, such as specific
nasal provocation and inhalation [18], and use test [19]
because there is no standardized use tests material avail-
able and for the risk of anaphylactic reactions [20,21].
Furthermore the challenge test does not exclude adverse
reactions in the future.
Discussion
Latex allergy emerged relatively recently as an important
medical condition. Until 1979, rubber allergy, especially
from gloves, was usually in the form of a type IV delayed
hypersensitivity, contact dermatitis reaction [22]. In 1979,
Nutter described a woman with type I latex allergy having
used household NRL gloves manifested by contact urti-
caria [23]. With the rapidly increasing number of cases,
type I latex allergy became a major medical, occupational
health, medico-legal and financial problems during the
1990s [22,24]. By 1997, the US Food and Drug Adminis-
tration (FDA) had received more than 1700 reports of se-
vere allergic reactions to medical latex devices [25,26]. It
is estimated that more than 15 million people suffer from
latex allergy worldwide [9-11]. Among the general popula-
tion the range of sensitization is between 5% and 10%,
while in the healthcare workers it is approximately 10 to
17% [12].
Currently there is no agreement about guidelines and
patients study protocols and in literature there are no of-
ficial documents about it and there are discrepancies. In
fact, for example, while in Europe and in Canada extracts
for latex skin prick test are available [12], in the USA there
are no FDA-approved skin test reagents for latex [27]. The
only national and international guidelines concerning the
prevention and reduction of risk were drawn up in 2008
by an Italian research group [28].
The prevalence of latex allergy depends on the popula-
tion studied, ranging from 3% to 64%, being highest in
certain groups. However in literature there are no data
available about latex sensitization in elderly population
and this group of patients is not considered among the
populations most at risk.
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aged 65 or over, 10 patients resulted latex positive, with
a prevalence of sensitization of 11,4%, and if compared
to the general population of 912 total patients, this per-
centage decrease to 1% of all patients studied.
However, our results show that allergy to latex is a
growing disease that can occur at any age. We therefore
suggest to consider people aged over 65 affected by urticaria
and angioedema, contact dermatitis, respiratory and/or mu-
cosal reactions, adverse drug reactions and polisensitivity
for aeroallergens, as additional risk categories. In addition,
elderly patients are more vulnerable because of the frequent
presence of comorbidity that often requires hospitalization
and surgery. The failure to diagnose such an allergic disease
can result in serious consequences. It’s important to identify
patients at risk, to make a quick and correct diagnosis and
therefore to be able to manage the patient.
So, our proposal is to carry out the study for latex
allergy in the following patient-types:
 those aged from 65 to 86, with a peak in the range
75-79 years;
 those reporting diseases such as urticaria,
angioedema, adverse drug reactions, contact
dermatitis and finally asthma and polisensitivity to
aeroallergens;
 we also suggest the submission at the second level
in vivo tests (skin prick test) the patients with a
highly suspected clinical history for latex sensitivity,
even if the RAST is negative.
Conclusions
The increasing recognition of latex allergy needs a more
accurate investigation, starting from the clinical history.
In fact, in our study 2% of positive adult patients reported
hypersensitivity to latex, but the others had not experienced
any problems before retirement. This may be related to
more hours spent at home and the hobbies practiced. In
fact some of these patients reported having initiated activ-
ities such as scuba diving, bowling and stamp collecting. It
is important to perform a complete allergological study of
these patients to have as much scientific evidences as pos-
sible also because in literature there are no studies on latex
sensitization in the elderly.
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